1466558-30-4Relevant articles and documents
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain
Kester, Robert F.,Donnell, Andrew F.,Lou, Yan,Remiszewski, Stacy W.,Lombardo, Louis J.,Chen, Shaoqing,Le, Nam T.,Lo, Jennifer,Moliterni, John A.,Han, Xiaochun,Heather Hogg,Liang, Weiling,Michoud, Christophe,Rupert, Kenneth C.,Mischke, Steven,Le, Kang,Weisel, Martin,Janson, Cheryl A.,Lukacs, Christine M.,Fretland, Adrian J.,Hong, Kyoungja,Polonskaia, Ann,Gao, Lin,Li, Shirley,Solis, Dave S.,Aguilar, Doug,Tardell, Christine,Dvorozniak, Mark,Tannu, Shahid,Lee, Edmund C.,Schutt, Andy D.,Goggin, Barry
, p. 7788 - 7803 (2013)
The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of the BIR domains to the pro-apoptotic caspases. The BIR3 domain of XIAP binds and inhibits caspase 9, while the BIR2 domain binds and inhibits the terminal caspases 3 and 7. While XIAP BIR3 inhibitors have previously been reported, they also inhibit cIAP1/2 and promote the release of TNFα, potentially limiting their therapeutic utility. This paper will focus on the optimization of selective XIAP BIR2 inhibitors leading to the discovery of highly potent benzodiazepinone 36 (IC50 = 45 nM), which has high levels of selectivity over XIAP BIR3 and cIAP1 BIR2/3 and shows efficacy in a xenograft pharmacodynamic model monitoring caspase activity while not promoting the release of TNFα in vitro.
2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER
-
, (2015/09/22)
Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer.
